Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial.
Sign Up to like & getrecommendations! Published in 2021 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2021.3836
Abstract: Importance Isocitrate dehydrogenase 1 (IDH1) variations occur in up to approximately 20% of patients with intrahepatic cholangiocarcinoma. In the ClarIDHy trial, progression-free survival as determined by central review was significantly improved with ivosidenib vs placebo.… read more here.
Keywords: trial; cholangiocarcinoma idh1; idh1 mutation; placebo ... See more keywords
Characterization of iPSCs derived from low grade gliomas revealed early regional chromosomal amplifications during gliomagenesis
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Neuro-Oncology"
DOI: 10.1007/s11060-018-03047-1
Abstract: IntroductionIDH1 mutation has been identified as an early genetic event driving low grade gliomas (LGGs) and it has been proven to exerts a powerful epigenetic effect. Cells containing IDH1 mutation are refractory to epigenetical reprogramming… read more here.
Keywords: ipsc clones; regional chromosomal; idh1 mutation; grade gliomas ... See more keywords
Reliability of noncontrast-enhancing tumor as a biomarker of IDH1 mutation status in glioblastoma
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Neuroscience"
DOI: 10.1016/j.jocn.2017.01.007
Abstract: Isocitrate dehydrogenase 1 (IDH1) mutations in gliomas have been associated with a frontal lobe location and a greater proportion of noncontrast-enhancing tumour (nCET). The purpose of our study was to validate the utility of MRI… read more here.
Keywords: idh1 wildtype; glioblastoma; frontal lobe; idh1 ... See more keywords
Combination of isocitrate dehydrogenase 1 (IDH1) mutation and podoplanin expression in brain tumors identifies patients at high or low risk of venous thromboembolism
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Thrombosis and Haemostasis"
DOI: 10.1111/jth.14129
Abstract: Essentials Risk stratification for venous thromboembolism (VTE) in patients with brain tumors is challenging. Patients with IDH1 wildtype and high podoplanin expression have a 6‐month VTE risk of 18.2%. Patients with IDH1 mutation and no… read more here.
Keywords: mutation podoplanin; podoplanin; idh1 mutation; podoplanin expression ... See more keywords
IDH1 mutation predicts response and survival in treatment-naïve Acute Myeloid Leukemia patients receiving with venetoclax with a hypomethylating agent
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-7032
Abstract: Introduction Venetoclax + hypomethylating agent (Ven-HMA) is currently the standard frontline therapy for older/unfit patients (pts) with newly diagnosed acute myeloid leukemia (ND-AML) based on VIALE-A trial results. Post-hoc analyses of the VIALE-A trial showed… read more here.
Keywords: treatment; survival; response; risk ... See more keywords
CT-based radiogenomic signature to identify isocitrate dehydrogenase (IDH)1/2 mutations in advanced intrahepatic cholangiocarcinoma.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.4081
Abstract: 4081 Background: IDH1/2 mutations have a high prevalence (20%) in intrahepatic cholangiocarcinoma (iCCA) and can be associated with therapeutic benefit from IDH inhibitors. Radiomics, a developing field within imaging, has shown its ability to discriminate… read more here.
Keywords: intrahepatic cholangiocarcinoma; idh1 mutation; signature; radiogenomic signature ... See more keywords
IDH1 mutation is associated with lower expression of VEGF but not microvessel formation in glioblastoma multiforme
Sign Up to like & getrecommendations! Published in 2018 at "Oncotarget"
DOI: 10.18632/oncotarget.24536
Abstract: Introduction Glioblastoma multiforme (GBM) represents the most malignant primary brain tumor characterized by pathological vascularization. Mutations in isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) were observed in GBM. We aimed to assess the intra-tumor… read more here.
Keywords: gbm; glioblastoma multiforme; idh1 mutation; expression ... See more keywords
Simplified Perfusion Fraction from Diffusion-weighted Imaging in Preoperative Prediction of IDH1 Mutation in WHO Grade II–III Gliomas: Comparison with Dynamic Contrast-enhanced and Intravoxel Incoherent Motion MRI
Sign Up to like & getrecommendations! Published in 2020 at "Radiology and Oncology"
DOI: 10.2478/raon-2020-0037
Abstract: Abstract Background Effect of isocitr ate dehydrogenase 1 (IDH1) mutation in neovascularization might be linked with tissue perfusion in gliomas. At present, the need of injection of contrast agent and the increasing scanning time limit… read more here.
Keywords: diffusion; perfusion; idh1 mutation; mri ... See more keywords
Prediction of IDH1-Mutation and 1p/19q-Codeletion Status Using Preoperative MR Imaging Phenotypes in Lower Grade Gliomas
Sign Up to like & getrecommendations! Published in 2018 at "American Journal of Neuroradiology"
DOI: 10.3174/ajnr.a5421
Abstract: BACKGROUND AND PURPOSE: WHO grade II gliomas are divided into three classes: isocitrate dehydrogenase (IDH)-wildtype, IDH-mutant and no 1p/19q codeletion, and IDH-mutant and 1p/19q-codeleted. Different molecular subtypes have been reported to have prognostic differences and… read more here.
Keywords: codeletion; grade; idh1 mutation; lower grade ... See more keywords
Frequency of IDH1 mutation in adult-type diffuse astrocytic gliomas in a tertiary hospital in Kenya
Sign Up to like & getrecommendations! Published in 2024 at "Frontiers in Medicine"
DOI: 10.3389/fmed.2024.1305714
Abstract: The 2021 WHO classification of gliomas has separated gliomas based on their IDH mutation status, reflecting differences in their pathogenesis and clinical characteristics. There is a paucity of data on the prevalence of IDH mutations… read more here.
Keywords: mutation adult; frequency idh1; mutation; gliomas ... See more keywords
CDKN2A Homozygous Deletion Is a Stronger Predictor of Outcome than IDH1/2-Mutation in CNS WHO Grade 4 Gliomas
Sign Up to like & getrecommendations! Published in 2024 at "Biomedicines"
DOI: 10.3390/biomedicines12102256
Abstract: Background: We primarily investigated the prognostic role of CDKN2A homozygous deletion in CNS WHO grade 4 gliomas. Additionally, we plan to examine traditional prognostic factors for grade 4 gliomas and validate the findings. Materials: We… read more here.
Keywords: deletion; grade gliomas; idh1 mutation; cns grade ... See more keywords